Predict your next investment

Corporation
MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Travel
park-now.com

See what CB Insights has to offer

Partners & Customers

1

About Park Now

Park Now is a parking app that streamlines parking into something simple, quick and effortless for users.On March 9th, 2021, Park Now was acquired by Easypark. The terms of the transaction were not disclosed.

Park Now Headquarter Location

Brunnenstraße 19-21

Berlin, 10119,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Park Now News

EasyPark Group’s acquisition of PARK NOW Group is complete

Jun 1, 2021

STOCKHOLM, June 1, 2021 /PRNewswire/ — Authorities have announced their approval of EasyPark Group’s acquisition of the global provider of digital parking services, PARK NOW Group. Thereby, EasyPark Group today announced the closing of the transaction and PARK NOW Group is a part of EasyPark Group from June 1, 2021. On March 9, EasyPark Group announced the intended acquisition of the global provider of digital parking services, PARK NOW Group. The acquisition has now been unconditionally approved by the relevant antitrust authorities, and all assets and liabilities have been transferred from the shareholders BMW Group and Daimler Mobility AG to EasyPark Group. The acquisition enables EasyPark Group to grow further and become a global pacesetter within digital parking, electrical vehicle charging and mobility services. The two companies are perfectly positioned with a complementary market coverage in Northern America, Australia, New Zealand, UK (covering England, Scotland, Northern Ireland, Wales) and rest of Europe, with a growing reach of currently 3,200 cities globally. Following the closing of the acquisition, Jörg Reimann steps down from his role as CEO for PARK NOW Group and Johan Birgersson, CEO of EasyPark Group, takes over as CEO of the expanded Group. – This is a historic milestone in the industry, and we are very excited to embark on this journey. Most of all, I am proud to be leading such a strong organization with talented employees. With global coverage and scale, as well as an integrated portfolio, we will be able to make cities more liveable by driving the development of new, smart and integrated digital services, says Johan Birgersson, CEO of EasyPark Group. – We are delighted to see the combination of two successful companies creating a pacesetter in the field of digital parking services. Park Now Group and EasyPark are a perfect match that will provide attractive and innovative offerings for customers worldwide, says Stephan Unger, Member of the Board of Management of Daimler Mobility for Finance, Controlling, Risk Management and Digital Mobility Solutions. – The approved acquisition of PARK NOW Group is the starting point of a new era of EasyPark Group. It will raise the joint operations to a new level and thus foster innovation and increase customer benefit. Together, EasyPark Group and PARK NOW Group will be able to provide a wide range of digital parking services, offering ever more seamlessly integrated services to their customers, says Rainer Feurer, Senior Vice President of Corporate Investments at BMW Group. The integration of the two companies will be realized in several steps concerning commercial offerings, internal organization and ways of working. – We are now entering a discovery and integration phase where we will make sure to draw from the strength, knowledge and spirit of both PARK NOW Group and EasyPark Group, to build our future success. Together we have a huge potential, and as one united company we will be able to offer even more value to drivers, businesses, cities and parking operators all around the world, says Johan Birgersson. The parties have agreed not to disclose the terms of the transaction. CONTACT: Trading in Valour Polkadot (DOT) SEK began May 31, 2021 on Nordic Growth Market stock exchange TORONTO, June 1, 2021 /PRNewswire/ – Valour Structured Products Inc. (“ Valour “), a subsidiary of DeFi Technologies Inc. (the “Company” or “DeFi Technologies”) (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF) and issuer of investment products focused on digital assets, has launched its Polkadot ETP (VALOUR POLKADOT (DOT) SEK – CH1114178770) on the Nordic Growth Market (NGM) stock exchange. The Valour Polkadot ETP enables investors to gain exposure to DOT, the native token of the Polkadot protocol, simply and securely, via their bank or broker. Polkadot  is a next generation blockchain protocol that enables interoperability and scalability for multiple blockchains. An open-source project founded by the Web3 Foundation , Polkadot’s native token, DOT, carries out three essential functions: providing governance for the network, operating the network via staking, and supporting the creation of parachains, specialized blockchains that connect to Polkadot. Polkadot is among the top ten cryptocurrencies in the world by market capitalization1, currently at USD $19.7 billion. By gaining exposure to digital assets via Valour, investors of DeFi Technologies benefit from the standardisation, risk reduction and operational efficiency of a centrally-cleared product listed on a regulated stock exchange. For each exchange traded product of Valour that is bought and sold on the stock exchange, Valour purchases or sells the equivalent amount of the underlying digital assets, meaning the products are fully backed at all times. _____________________________ Coinmarketcap.com as at 31 May 2021 “We’re thrilled to be the first to bring a Polkadot ETP to the Nordics,” said Valour CEO Diana Biggs. “This is a particularly exciting time for the Polkadot protocol with the upcoming launch of its parachain functionality, providing increased scalability and finalizing its core build. Our launch of Valour DOT SEK is a direct response to increased demand from both retail and institutional investors for access to further innovative blockchain protocols via our ETPs,” she added. “Amazing to see another successful launch by the team. With Polkadot we have now listed our second DeFi pure play ETN in May,” said Wouter Witvoet, CEO of DeFi Technologies. “Polkadot has some of the smartest people behind the project, including the co-founder of Ethereum, Thiel Fellows, and artificial intelligence experts. The potential for Polkadot to make it easier than ever to create and connect decentralized applications, services, and institutions is an exciting prospect for the larger DeFi ecosystem.” DeFi Technologies also announces that it has engaged Native Ads Inc. to execute a comprehensive digital media marketing campaign for the Company. This programmatic digital advertising campaign will run for a 12-month period at a cost of approximately C$312,500, and is to include content creation, web development, media buying and distribution, advertising creative development, campaign reporting and optimization. About Valour Polkadot (DOT) SEK Valour Polkadot (DOT) SEK (ISIN: CH1114178770) is a fully-hedged, passive investment product with Polkadot’s native token, DOT, as its underlying asset. The new Valour Polkadot ETP, available in Swedish krona, is traded on the Nordic Growth Market (NGM), a regulated stock exchange based in Stockholm, Sweden, under local ticker VALOUR POLKADOT SEK. Available for purchase via banks or brokers in the same way as any other security, the ETP removes the mystery, complexity and costs of DOT investment and custody that have thus far impeded mainstream adoption of digital assets and decentralised finance. About Valour Valour Structured Products Inc. issues exchange-listed financial products that enable retail and institutional investors to access investment in disruptive innovations, such as digital assets, in a simple and secure way. Established in 2019 and based in Zug, Switzerland, Valour is a wholly owned subsidiary of DeFi Technologies Inc. (NEO:DEFI, GR: RMJ.F, OTC: DEFTF). For more information on Valour, visit www.valour.com . About DeFi Technologies DeFi Technologies Inc. is a Canadian company that carries on business with the objective of enhancing shareholder value through building and managing assets in the decentralized finance sector. For more information visit https://defi.tech/ . About Native Ads Inc. Native Ads is a full-service ad agency that owns and operates a proprietary ad exchange with over 80 integrated SSPs (supply-side platforms) resulting in daily access to three to seven billion North American ad impressions. Cautionary note regarding forward-looking information:  This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the growth and adoption of decentralized finance; the pursuit by DeFi Technologies of business opportunities; the offering and trading of Polkadot ETP on the NGM; the engagement of Native Ads and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. THE NEO STOCK EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE SOURCE DeFi Technologies, Inc. SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ —  Mirati Therapeutics, Inc. (NASDAQ: MRTX ), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB ; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan). “We believe Zai Lab is an ideal partner to enable us to expand and accelerate Mirati’s global adagrasib development,” said Charles M. Baum, M.D., Ph.D. , president and chief executive officer, Mirati Therapeutics, Inc. “Zai Lab has an established record of rapid and high quality development and commercialization of innovative oncology product candidates in China. Their capabilities position Mirati to further develop adagrasib for patients with cancer who harbor the KRASG12C mutation around the world.”  “We are delighted to collaborate with Mirati to bring adagrasib to patients in need in Greater China as soon as possible,” said Samantha Du, Ph.D., founder, chairperson, and chief executive officer of Zai Lab. “Lung cancer is the most common cancer in China, and we aim to make adagrasib an important product in our growing lung cancer franchise. We are also excited about the potential of adagrasib to treat colorectal, pancreatic and other cancers characterized by KRASG12C mutations.” Under the terms of the agreement, Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Zai Lab will support accelerated enrollment in key global, registration-enabling clinical trials of adagrasib in patients with cancer who have a KRASG12C mutation. Mirati has an option to co-commercialize in Greater China and retains full and exclusive rights to adagrasib in all countries outside of Greater China. Mirati will receive a $65 million upfront payment, with the potential to receive up to an additional $273 million in development, regulatory and sales-based milestone payments. Mirati is also eligible to receive high-teen- to low-twenties-percent tiered royalties based on annual net sales of adagrasib in Greater China. About Adagrasib (MRTX849) Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C mutated cancers, which regenerates every 24-48 hours. Studies of adagrasib have shown that the drug has a long half-life and extensive tissue distribution and is well tolerated. Adagrasib has shown single-agent responses in non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations. Adagrasib is also being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors. Registration-enabling studies are ongoing in NSCLC and colorectal cancer. For more information visit Mirati.com/science . About NSCLC and Colorectal Cancer in China KRASG12C is the most common KRAS mutation in non-small cell lung cancer (NSCLC). The mutation is a biomarker of poor prognosis in Chinese patients with NSCLC. Lung cancer consists of NSCLC in approximately 85% of cases and small cell lung cancer (SCLC) in approximately 15% of cases. According to the World Health Organization, the incidence of lung cancer in China in 2020 was 815,563 cases, with 714,699 deaths. Colorectal cancer (CRC) is the second most commonly diagnosed cancer type in China. According to the World Health Organization, the incidence of colorectal cancer in China in 2020 was 550,628 cases, with 283,751 deaths. About Mirati Therapeutics Inc. Mirati Therapeutics Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati Therapeutics Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn . About Zai Lab Zai Lab (NASDAQ: ZLAB ; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. Our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of potentially innovative, marketed products and product candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to positively impact human health worldwide. For additional information about the company, please visit  www.zailaboratory.com  or follow us at  www.twitter.com/ZaiLab_Global . Mirati Therapeutics Forward Looking Statements   This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation adagrasib (MRTX849), sitravatinib and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Mirati’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati’s programs are described in additional detail in Mirati’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the “SEC”) available at the SEC’s Internet site ( www.sec.gov ).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Zai Lab Forward-Looking Statements This press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects and plans for developing and commercializing adagrasib in Greater China and other statements containing words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab’s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab’s ability to successfully commercialize and generate revenue from its approved products; (2) Zai Lab’s ability to finance its operations and business initiatives and obtain funding for such activities, (3) Zai Lab’s results of clinical and pre-clinical development of its product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab’s product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on our business and general economic, regulatory and political conditions and (6) the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab’s expectations and assumptions to change and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab’s views as of any date subsequent to the date of this press release. Mirati Contacts Media Relations: Priyanka Shah | 908-447-6134 | [email protected] Zai Lab Contacts This is one of the largest government contracts Alithya has been awarded in Québec in recent years. As part of this five-year contract, Alithya’s professionals will offer leading-edge expertise and support to the client, and provide their teams with the response capability to fully carry out their major responsibilities in managing information resources projects. Quote from Dave Moreau, Senior Vice President, Public Sector: “We are pleased to have won this contract. It shows that the wide variety of projects we have managed over the years made us highly adaptable and very knowledgeable about the government sector. As a result, we have developed a customized approach based on best practices and the evolution of project management tools. Regardless of the direction government agencies are taking, Alithya knows how to align the management strategy with the project’s objectives to further tangible initiatives.” About Alithya and its service offerings for government organizations Alithya is a North American leader in strategy and digital transformation. The company employs more than 3,000 professionals in Canada, the US and Europe. Alithya’s integrated offer is based on four pillars of expertise: business strategies, enterprise cloud solutions, application services, and data and analytics. As a qualified service provider in the Catalogue of cloud computing offers from the Centre d’acquisitions gouvernementales du Québec, Alithya assists Québec public agencies in their technological shift. To learn more about Alithya’s innovative solutions and services meeting the objectives of public sector clients regarding both the business and technological aspects of projects, visit https://www.alithya.com/en/industries/government. SOURCE Alithya

Park Now Acquisitions

1 Acquisition

Park Now acquired 1 company. Their latest acquisition was Parkling on September 23, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/23/2019

Acquired

1

Date

9/23/2019

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

1

Park Now Partners & Customers

1 Partners and customers

Park Now has 1 strategic partners and customers. Park Now recently partnered with BMW Group on March 3, 2012.

Date

Type

Business Partner

Country

News Snippet

Sources

3/21/2012

Partner

BMW Group

Germany

Rent an EV, Find Parking in SF With BMW and ParkNow

BMW has partnered with Coulomb Technologies ' ChargePoint network so that drivers can locate charging stations using an onboard navigation system if they need juice for their EV rental .

1

Date

3/21/2012

Type

Partner

Business Partner

BMW Group

Country

Germany

News Snippet

Rent an EV, Find Parking in SF With BMW and ParkNow

BMW has partnered with Coulomb Technologies ' ChargePoint network so that drivers can locate charging stations using an onboard navigation system if they need juice for their EV rental .

Sources

1

Park Now Team

2 Team Members

Park Now has 2 team members, including current Chief Executive Officer, Jorg Reimann.

Name

Work History

Title

Status

Jorg Reimann

Chief Executive Officer

Current

Marc de Vries

Chief Executive Officer

Former

Name

Jorg Reimann

Marc de Vries

Work History

Title

Chief Executive Officer

Chief Executive Officer

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.